Core Insights - Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise in immunology and infectious diseases, which aligns with the company's therapeutic focus and clinical development roadmap [1][9] Group 1: New Appointments - Dr. Taku Kambayashi is a Professor at the University of Pennsylvania with expertise in immune cell signal transduction pathways, focusing on therapies for autoimmune and inflammatory diseases [2][3] - Dr. Selvakumar Subbian is a Professor at Rutgers University with over 25 years of experience in microbial pathogenesis, particularly in pulmonary infectious diseases like tuberculosis and COVID-19 [5][6] Group 2: Research Contributions - Dr. Kambayashi's research includes TSLP-stimulated T cells and their implications for obesity-related disorders, as well as therapeutic manipulation of regulatory T cell homeostasis in diseases such as multiple sclerosis and diabetes [3][4] - Dr. Subbian's laboratory has developed rabbit models for studying tuberculosis, contributing to host-directed therapy that enhances antibiotic efficacy [6][8] Group 3: Company Overview - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, showing anti-inflammatory properties and a history of human use in China [10][11] - Phyto-N has been validated in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis, and is preparing for an Investigational New Drug (IND) submission [11]